Monkeypox Treatment Market, By Type of Treatment (Prophylactic, and Therapeutics), By Route of Administration (Oral, and Injectable), By Sales Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Region Analysis - Global Analysis And Industry Forecast Report Till 2030.

The Monkeypox Treatment Market is projected to grow from $70.2 million to $288.41 million, at a CAGR of 17% during the forecast period 2021-2030.

In 1958, monkeypox was discovered in two outbreaks of a chickenpox-like disease in a population of monkeys kept for study. Monkeypox virus is the cause of this disease. It is a disease that is transmitted to humans from animals. The viruses that cause smallpox and monkeypox both belong to the same family of viruses. It is less harmful than smallpox, though. Smallpox symptoms are comparable to those of monkey pox, although they are less severe and typically not as harmful to health.

Central and West Africa are more susceptible to monkeypox. However, Western and European regions are also vulnerable to monkeypox because of the 2022 outbreak. Due to advancements in the mode of treatment of monkeypox, this market is expected to have escalating growth.

Monkeypox treatment involves a comprehensive approach aimed at managing the symptoms and facilitating the recovery of affected individuals. The primary goal of treatment for monkeypox is to alleviate the discomfort caused by the viral infection. Currently, there is no specific cure for monkeypox; however, medical professionals focus on symptomatic relief and supportive care to enhance the body's ability to fight the virus. Treatment options may include antiviral medications, pain relievers, and antipyretics to reduce fever. Additionally, measures such as maintaining good personal hygiene, avoiding close contact with infected individuals, and managing monkeypox rash through gentle cleansing and the application of soothing creams can aid in the overall management of the disease.

Market Dynamics:

Drivers:

The increasing incidence of monkeypox disease is expected to drive the demand for new drugs and vaccines for the treatment of this disease. This is expected to drive the global monkeypox treatment market growth over the forecast period.

According to the Centers for Disease Control and Prevention, demand for vaccines in the United States is exceeding the vaccine supply. Therefore, the huge demand for monkeypox vaccines and treatments is expected to drive the growth of the monkeypox treatments market globally.

Restraints:

A major restraint in the global monkeypox treatment market is the increasing side effects associated with drugs used to treat this disease, which may hamper the growth of the market. Minor upset stomach, dry mouth, difficulty concentrating, and malaise are the main side effects of the medications used to treat Monkeypox. A lack of qualified personnel who are unable to treat patients with appropriate treatment may restrain the growth of the global monkeypox market during the forecast period. These factors are expected to constrain market growth.

Opportunities:

Genome sequencing of viruses will reveal specific infection-causing sequences that will aid in the early diagnosis of viral infections and the development of effective vaccines for future at-risk populations. Additionally, rising healthcare expenditures by the population are driving investments in developing new vaccines, which will spur the global monkeypox treatment market over the forecast period. Currently, Tecovirimat is the treatment of choice for those treating monkeypox. This is expected to boost growth over the forecast period and are contributing to bringing many opportunities in this market.

Key Players:

• Bavarian Nordic

• SIGA Technologies

• Chimerix

• BioFactura, Inc.

• Tonix Pharmaceuticals Holding Corp.

• SymBio Pharmaceuticals Limited

• Gilead Sciences, Inc.

• Aspen Holdings

• Emcure Pharmaceuticals

• Baxter

• Grifols S.A.

• EMERGENT

• Hetero

• Olon S.P.A.

• Piramal Enterprises Ltd.

Market Segmentation:

Monkeypox Treatment Market, By Type of Treatment

• Prophylactic

• Therapeutic

Monkeypox Treatment Market, By Sales Channel

• Retail Pharmacies

• Hospital Pharmacies

• Online Pharmacies

Monkeypox Treatment Market, By Administration Route

• Oral

• Injectable

Monkeypox Treatment Market, By Region Type

• North America 

• Europe 

• Asia-Pacific 

• LAMEA 

Regional Analysis:

North America dominated the market with a revenue share in 2022. It is regarded as the largest region in this market, owing to the presence of multiple key players and various strategic initiatives undertaken by them. In addition, rising disease prevalence and increasing people's awareness about vaccination are expected to spur the expansion of the regional market. Moreover, favorable government support and increased R&D investment are expected to provide lucrative growth opportunities for North America.

Asia Pacific is expected to witness the fastest growth during the forecast period. An increase in the number of monkeypox infections and increasing R&D to develop prevention and treatment options are some of the major factors driving the market. The increasing infection spread in Asia Pacific countries such as Australia, Singapore, and India is expected to propel market growth.

Scope of the report:

User

Tab Content